Clarevia Ventures has appointed healthcare investor and analyst Margaret Kaczor Andrew as a venture partner, expanding the firm’s work with early-stage medical technology and clinical innovation companies. In the role, she will source, evaluate, and support investments across medical devices, clinical technologies, and emerging healthcare platforms. The Madison, Wisconsin-based venture capital firm said the appointment will strengthen its ability to help founders move scientific advances toward commercial scale and patient impact.
Strengthening Healthcare Investment Expertise
Kaczor Andrew brings more than 15 years of experience spanning healthcare innovation, capital markets and the adoption of clinical technologies. Her background will inform Clarevia’s early-stage investment process, where the ability to assess a technology’s route from development to market can be as important as the underlying science. She also brings relationships across the healthcare investment ecosystem, including connections in the Chicago area that Clarevia expects will enhance its regional reach.
Jim Adox, managing partner at Clarevia, said Kaczor Andrew’s experience will help the firm identify and support companies capable of reshaping healthcare delivery. He pointed to her understanding of the way clinical technologies are evaluated, adopted and scaled in demanding healthcare markets. That perspective matters for startups that must balance clinical validation, customer demand, reimbursement considerations and long-term business development.
Perspective on Clinical Adoption
Before joining Clarevia, Kaczor Andrew spent 15 years at William Blair, where she was a partner and sell-side equity research analyst. Her work focused on clinical innovation and the adoption dynamics that influence long-term value creation across healthcare businesses. She advised investors, management teams and companies on market strategy, competitive positioning, fundraising and new business opportunities.
Her interests span medical technology solutions for unmet needs in consumer health technology, cardiology, neurology, diabetes, aesthetics, respiratory care and ophthalmology. Clarevia said she pairs detailed market analysis with a practical understanding of how a clinical concept progresses from promising data to real-world use. The firm expects that approach to support investment decisions that account for both technical differentiation and the commercial conditions required for broader adoption.
Supporting Founders Beyond Funding
Kaczor Andrew said she is looking forward to working with entrepreneurs and investors developing meaningful healthcare innovations. She said there is a significant opportunity to better connect clinical insight with investment strategy, especially in sectors where product development, evidence generation and market access can take years. Her arrival reflects Clarevia’s view that founders building in complex clinical markets require support that goes beyond capital alone.
Clarevia provides financing, operational guidance and strategic counsel to companies developing healthcare products and platforms. The firm emphasises disciplined investment, clear priorities and long-term partnership as companies work through research, validation, regulatory processes and commercialisation. Its portfolio includes HistoSonics, Neurovance and EarliPoint, which illustrate its focus on helping scientific breakthroughs find a path toward patient care.
Founded in 1984, Clarevia Ventures focuses on backing healthcare companies at early and often overlooked stages of development. Adding Kaczor Andrew gives the firm additional expertise in clinical adoption, market dynamics and healthcare strategy as it evaluates new opportunities. The appointment reinforces Clarevia’s stated goal of pairing specialised investment support with the expertise needed to turn promising healthcare science into sustainable businesses and improved patient outcomes.